Literature DB >> 25371243

Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.

Parsia A Vagefi1, Jennifer L Dodge, Francis Y Yao, John P Roberts.   

Abstract

A subset of liver transplantation (LT) recipients who undergo transplantation for hepatocellular carcinoma (HCC) will develop postoperative recurrence. There has yet to be a thorough investigation of donor factors influencing recurrence. Data regarding adult, primary LT recipients with HCC (n = 5002) who underwent transplantation between January 1, 2006 and September 30, 2010 were extracted from the United Network for Organ Sharing database, and the cumulative incidence of post-LT recurrence by donor factors was subsequently estimated. Among the HCC LT recipients, 324 (6.5%) developed recurrence. An analysis of donor characteristics demonstrated a higher cumulative incidence of recurrence within 4 years of transplantation among recipients with donors ≥ 60 years old (11.8% versus 7.3% with donors < 60 years old, P < 0.001) and with donors from a nonlocal share distribution (10.6% versus 7.4% with donors with a local share distribution, P = 0.004). The latter 2 findings held true in a multivariate analysis: the risk of HCC recurrence increased by 70% for recipients of livers from donors ≥ 60 years old [subhazard ratio (SHR) = 1.70, 95% confidence interval (CI) = 1.31-2.20, P < 0.001] and by 42% for recipients of nonlocal share distribution livers (SHR = 1.42, 95% CI = 1.09-1.84, P = 0.009) after adjustments for clinical characteristics. In conclusion, the consideration of certain donor factors may reduce the cumulative incidence of posttransplant HCC recurrence and thus improve long-term survival after LT.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25371243      PMCID: PMC4308564          DOI: 10.1002/lt.24042

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  18 in total

1.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Patient, center and geographic characteristics of nationally placed livers.

Authors:  J C Lai; J P Roberts; E Vittinghoff; N A Terrault; S Feng
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

3.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

4.  Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Francis Y Yao; John Paul Roberts
Journal:  Liver Transpl       Date:  2014-07-03       Impact factor: 5.799

5.  Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts.

Authors:  Kris P Croome; William Wall; Natasha Chandok; Gavin Beck; Paul Marotta; Roberto Hernandez-Alejandro
Journal:  Liver Transpl       Date:  2013-10-10       Impact factor: 5.799

6.  Hepatocellular carcinoma: Ablate and wait versus rapid transplantation.

Authors:  John P Roberts; Alan Venook; Robert Kerlan; Francis Yao
Journal:  Liver Transpl       Date:  2010-08       Impact factor: 5.799

7.  Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.

Authors:  Jennifer A Flemming; Parsia A Vagefi; Chris E Freise; Francis Y Yao; Norah A Terrault
Journal:  Liver Transpl       Date:  2014-09-03       Impact factor: 5.799

8.  Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.

Authors:  M Wali; R F Harrison; P J Gow; D Mutimer
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

9.  Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

Authors:  Marina Berenguer; Martín Prieto; Fernando San Juan; José M Rayón; Fernando Martinez; Domingo Carrasco; Angel Moya; Francisco Orbis; José Mir; Joaquín Berenguer
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Eric Vittinghoff; Francis Y Yao; John Paul Roberts
Journal:  Liver Transpl       Date:  2013-10-21       Impact factor: 5.799

View more
  9 in total

Review 1.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

Authors:  Gonzalo Sapisochin; Jordi Bruix
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

3.  Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria.

Authors:  Bianca Magro; Domenico Pinelli; Massimo De Giorgio; Maria Grazia Lucà; Arianna Ghirardi; Alessandra Carrobio; Giuseppe Baronio; Luca Del Prete; Franck Nounamo; Andrea Gianatti; Michele Colledan; Stefano Fagiuoli
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

Review 4.  Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.

Authors:  Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski
Journal:  Ann Transplant       Date:  2022-01-26       Impact factor: 1.530

5.  SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma.

Authors:  Qimeng Chang; Yayun Xu; Jianfa Wang; Hui Jing; Longhua Rao; Weiguo Tang; Ziping Zhang; Xubo Wu
Journal:  Comput Math Methods Med       Date:  2021-11-15       Impact factor: 2.238

Review 6.  Mitochondria and Cancer Recurrence after Liver Transplantation-What Is the Benefit of Machine Perfusion?

Authors:  Alessandro Parente; Mauricio Flores Carvalho; Janina Eden; Philipp Dutkowski; Andrea Schlegel
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

7.  Liver transplantation for hepatocellular carcinoma using grafts from uncontrolled circulatory death donation.

Authors:  Anisa Nutu; Iago Justo; Alberto Marcacuzco; Óscar Caso; Alejandro Manrique; Jorge Calvo; Álvaro García-Sesma; María García-Conde; María Santos Gallego; Carlos Jiménez-Romero
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

8.  Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation.

Authors:  Michał Grąt; Marek Krawczyk; Karolina M Wronka; Jan Stypułkowski; Zbigniew Lewandowski; Michał Wasilewicz; Piotr Krawczyk; Karolina Grąt; Waldemar Patkowski; Krzysztof Zieniewicz
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

9.  Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis.

Authors:  Faji Yang; Yuheng Zhang; Haozhen Ren; Jinglin Wang; Longcheng Shang; Yang Liu; Wei Zhu; Xiaolei Shi
Journal:  J Exp Clin Cancer Res       Date:  2019-12-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.